We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer

Bayer expects 2025 to be the most difficult year of its turnaround

Lupin receives USFDA approval for Tolvaptan Tablets

Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease

Caplin Steriles gets USFDA approval for Phytonadione Injectable Emulsion

Phytonadione Injectable Emulsion possesses the same type and degree of activity as does naturally-occurring vitamin K

Eugia Pharma receives USFDA approval for Dasatinib Tablets

Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia

Cosmo First to acquire veterinary clinic

The transaction is expected to be completed by May 15, 2025 or such other date as may be mutually agreed

Paras Healthcare introduces radiation oncology facility at Ranchi

The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home

FUJIFILM launches advanced therapeutic endoscopy system in India

The system is powered by advanced imaging innovations such as Amber-red Color Imaging, Triple Noise Reduction, and Extended Dynamic Range Image Processing

AstraZeneca, Daiichi Sankyo announce Enhertu plus pertuzumab demonstrated clinically meaningful improvement as 1st-line therapy for patients with metastatic breast cancer

DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care

Vgenomics and Meril Genomics collaborate to revolutionise precision medicine

Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide

Shin-Etsu Chemical and Hokkaido University develop lipid nanoparticle production system capable of both small-batch, high-mix production